ClinicalTrials.gg
CompletedNCT03310073Updated Nov 8, 2017

Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV

A Phase 4 interventional study of bOPV and Pentabio in Healthy, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to participants aged 1 Minute to 1 Day, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by PT Bio Farma · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2016, registered Apr 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
143
Allocation
Not applicable
Ages
1 Minute to 1 Day
Sex
All
01

Study summary

This study is to assess protectivity following four doses of bOPV which given simultaneously with Pentabio® and 1 dose of IPV at the 4th visit

Read the detailed description

To describe serological response after four doses of bOPV with 1 dose of IPV. To describe the antibody status to polio 60 days after birth dose of bOPV To assess the safety of bOPV which given simultaneously with Pentabio® and 1 dose 1 dosde of IPV at the 4th visit

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 1 Day
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, full term, newborns infants.
  • Newborns residing within a relatively short and easily accessible distance (\<30 km) from the study clinic(s) and not planning to travel away during the entire study period.
  • Infant born after 37 weeks of pregnancy
  • Infant weighing 2.5 kg or more at birth (Birth weight > 2.5 kg)
  • Healthy newborns, with no history of asphyxia or meconium aspiration.
  • Father, mother or legally acceptable representative properly informed about the study and having signed the form.
  • Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial.
  • Mother at least elementary school graduate

Exclusion criteria

Exclusion Criteria:

  • Child concomitantly enrolled or scheduled to be enrolled in another trial
  • Known history of congenital or acquired immunodeficiency (including infection)
  • Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature ≥ 37.5°C )
  • Newborns requiring hospitalization at birth.
  • Infant immunized with non-scheduled bOPV or IPV during trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    bOPV (bivalent OPV Bio Farma)

    bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally. The subject received bOPV, Pentabio and IPV according to the study schedule.

    Biological: bOPV · Biological: Pentabio · Biological: IPV

Interventions

  • BiologicalbOPV

    Batch Number: 2042015

    Also known as: bivalent Oral Polio Vaccine

  • BiologicalPentabio

    Batch number: 5050115 The vaccine shall be given intramuscularly.

    Also known as: DTP-HB-Hib Vaccine

  • BiologicalIPV

    The vaccine shall be given intramuscularly.

06

What researchers measure

Primary outcomes

  1. Number of subjects with anti polio titer ≥ 8 for type 1, 2 and type 3

    Evaluate protectivity

    Time frame: 30 days after the last vaccination

Secondary outcomes

  1. Percentage of infants with increasing antibody titer >= 4 times

    Serological response after four doses of bOPV with 1 dose of IPV

    Time frame: 30 days after the last vaccination

  2. Percentage of infants with transition of seronegative to seropositive

    Serological response after four doses of bOPV with 1 dose of IPV

    Time frame: 30 days after the last vaccination

  3. Geometric Mean Titer (GMT) after four doses of bOPV with 1 dose of IPV

    Geometric Mean Titer (GMT) 30 days after the last vaccination

    Time frame: 30 days after the last vaccination

  4. Number and severity of systemic adverse events (AEs) after each dose of bOPV, which given simultaneously with Pentabio and 1 dose of IPV

    Assess the safety of bOPV

    Time frame: first 30 minutes, 24hour, 48hour, 72hour and 30 days after vaccination.

  5. Number of serious adverse events (SAE) which occured during the study

    Assess the safety of bOPV

    Time frame: 30 days after the last vaccination

07

Study locations

1 site
  • Hasan Sadikin Hospital
    Bandung, West Java 40161, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Mar 2017, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2017
First posted
Oct 16, 2017
StartActual
Jul 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03310073
Lead sponsor
PT Bio Farma
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
Jul 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Nov 8, 2017

Study contacts

Kusnandi Rusmil
principal investigator · Hasan Sadikin General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Poliovirus Vaccine, Oral · Poliovirus Vaccine, Inactivated

Start the discussion